World premiere in stem cell research in MontrealApril 17, 2009Researchers at IRIC succeed in multiplying blood cells in the lab, accelerating the development of novel treatments for patients waiting for a bone marrow transplant A team from the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal has succeeded in producing a large quantity of laboratory stem cells from a small number of blood stem cells obtained from bone marrow. The multidisciplinary team, directed by Dr. Guy Sauvageau, thus took a giant step towards the development of a revolutionary treatment based on these stem cells. This worldwide first will advance stem cell research and could have major implications in several fields for which no treatment currently exists. Every year in North America, nearly 4,000 people wait in vain for a bone marrow transplant due to the lack of compatible donors. It is known that a bone marrow stem cell transplant can reconstitute the recipient's bone marrow. The main difficulty is to obtain a sufficient number of compatible stem cells. Thanks to Dr. Sauvageau and his team, these patients will be able to obtain new bone marrow within the next few years. "It could be possible to envision transplants for all adults from existing umbilical cord blood banks. The stem cell content of these blood banks is currently too limited for large-scale use in adults," Dr. Sauvageau affirmed. Organ transplants without side effects: the medicine of the future? Currently, transplant recipients are condemned to take medications against rejection of the transplanted organ and suffer the side effects for the rest of their lives. However, "mouse studies exist, showing that bone marrow stem cells can prevent the rejection typically directed against solid organs," Dr. Sauvageau said. Rejection occurs because the immune system cells manufactured by bone marrow attack the transplanted organ as if it were an invader. By extrapolation from laboratory studies, it is very likely that transplanting hematopoietic stem cells collected from the organ donor and developed in the laboratory could avoid rejection of this organ. This is why it is important to have large quantities of hematopoietic stem cells, so that compatible stem cells can be matched with the organ to be transplanted. Using proteins to multiply stem cells To produce large quantities of hematopoietic stem cells in the laboratory, Dr. Sauvageau's team identified 10 proteins out of 700 candidates. These 10 proteins are naturally present in hematopoietic stem cells and researchers can use each of them to force these cells to multiply in the laboratory. "The next step is to verify whether this also works in humans. Everything is already in place," Guy Sauvageau pointed out. These tests will be conducted at Montreal's Maisonneuve-Rosemont Hospital, one of the leading centres in Canada where stem cell transplants are performed. "If only one of the ten proteins allows hematopoietic stem cells to be multiplied in humans, we will be able to obtain the quantities of cells necessary to perform transplants. It will then be possible to say "mission accomplished"." Researchers around the world are currently trying to harness the regenerative power of other types of stem cells to treat diseases such as Alzheimer's or diabetes. IRIC's research could also help them achieve their goal. The work of Dr. Sauvageau's team has been funded by the Canadian Institutes of Health Research and the findings are being published today in the prestigious scientific journal Cell. University of Montreal |
|||||||||||||||||||||
| Related Bone Marrow Current Events and Bone Marrow News Articles Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Stem cell therapy may offer hope for acute lung injury Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease. New insight in the fight against the Leishmania parasite Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated. 2-million-year-old evidence shows tool-making hominins inhabited grassland environments In an article published in the open-access, peer-reviewed journal PLoS ONE on October 21, 2009, Dr Thomas Plummer of Queens College at the City University of New York, Dr Richard Potts of the Smithsonian Institution National Museum of Natural History and colleagues report the oldest archeological evidence of early human activities in a grassland environment, dating to 2 million years ago. Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute. Multivisceral transplant survival rates improve with new treatment, says Pittsburgh study Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management. Van Andel Institute Researchers Find Gene that Could Lead to New Therapies for Bone Marrow Disease Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia. Body's immune system response to dental plaque varies by gender and race Will neglecting to brush your teeth damage more than just your smile? Can failing to attack dental plaque increase your risk of heart damage? Rare genetic disease successfully reversed using stem cell transplantation A recent study by Scripps Research Institute scientists offers good news for families of children afflicted with the rare genetic disorder, cystinosis. More Bone Marrow Current Events and Bone Marrow News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||